IR-MED

Company Overview

Snapshot

Founded in September 2012 by Ronnie Klein, IR-MED operates with 11–50 employees. The company has raised $8.73 million across five funding rounds. In May 2025, IR-MED was awarded a grant from the Israel Innovation Authority to advance its AI-powered DiaSafe™ device for Diabetic Foot Ulcer Assessment.

Business overview

IR-MED develops a non-invasive infrared spectroscopy and AI analysis technology platform for point-of-care decision support devices. This technology gathers bio-information from patient blood and tissue without harm, which is then analyzed by the company's AI to assist healthcare professionals in detecting and monitoring various disease conditions. Its flagship product, PressureSafe, is a handheld device designed for the early detection of pressure injuries, serving the healthcare industry by aiming to reduce the incidence and cost of such injuries.

Strategic signal

In May 2024, IR-MED's PressureSafe device demonstrated significant efficacy by reducing pressure injuries by 50% during a usability study with Clalit, Israel’s largest HMO. This outcome validates the device's potential to significantly improve patient care and reduce healthcare burdens, signaling strong clinical utility and market readiness for its non-invasive diagnostic technology.

Company Intelligence Q&A

What is IR-MED's primary focus in medical diagnostics?

IR-MED specializes in developing non-invasive infrared-based diagnostic technologies, utilizing AI analysis to provide decision support for healthcare professionals in detecting and monitoring various disease conditions.

When did IR-MED go public?

IR-MED became public on OTCQB in December 2020, following a reverse merger with International Display Advertising, Inc. and a private placement.

What is PressureSafe and its key benefit?

PressureSafe is IR-MED’s handheld device that uses infrared spectroscopy and AI for the early detection of pressure injuries. A key benefit is its ability to detect these injuries regardless of patient skin tone, promoting equitable healthcare.

Has IR-MED received any grants recently?

In May 2025, IR-MED was awarded a grant from the Israel Innovation Authority to advance its AI-powered DiaSafe device, which is designed for diabetic foot ulcer assessment. This followed another grant in July 2024 from the same authority for developing its platform technology for early detection of diabetic foot ulcers.

What was a significant clinical milestone for PressureSafe in 2024?

In May 2024, IR-MED's PressureSafe device demonstrated a 50% reduction in pressure injury incidence during a usability study conducted with Clalit, Israel’s largest HMO.